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In 2010, a total of 1327 clinical Escherichia coli isolates were analysed by PCR in 5 hospitals in the 24 
Kyoto and Shiga regions of Japan. The prevalence of plasmid-mediated AmpC β-lactamase (pAmpC) 25 
producers, extended-spectrum β-lactamase (ESBL) producers, and co-producers of pAmpC and ESBL 26 
were 1.7%, 9.7%, and 0.3%, respectively. Less than half of the pAmpC producers were reported to be 27 
resistant to third-generation cephalosporins, cephamycins, and β-lactam/β-lactam inhibitors with the 28 
old CLSI breakpoints in 2009. CMY-2 was the most prevalent pAmpC type (95%), and CTX-M-14 29 
(38%), CTX-M-15 (26%), and CTX-M-27 (19%) were the most prevalent ESBL types. The 30 
worldwide O25b-ST131-B2 clone accounted for 11% of pAmpC producers and 41% of ESBL 31 
producers. The O25b-ST131-B2 clone was characterised by a CTX-M-27 or CTX-M-15 type ESBL 32 
and ciprofloxacin non-susceptibility with quadruple mutations in quinolone resistance-determining 33 
regions (S83L and D87N in GyrA and S80I and E84V in ParC). A significant proportion of pAmpC 34 
producers and the O25b-ST131-B2 clone were found in Japan by a recent regional surveillance 35 
program. 36 
 37 




1. Introduction 40 
In recent years, the prevalence of extended-spectrum β-lactamase (ESBL)-producing 41 
Escherichia coli has increased dramatically worldwide [1]. A CTX-M-15 ESBL-producing E. coli 42 
with sequence type 131 (ST131) belonging to the O25b serogroup and the B2 phylogenetic group has 43 
emerged as an international pandemic clone[2]. The prevalence of plasmid-mediated AmpC 44 
β-lactamase (pAmpC)-producing E. coli has likewise been increasing [3]. As standard guidelines for 45 
detecting pAmpC remain unavailable, pAmpC producers are rarely identified in routine laboratory 46 
practices. However, the current data for the ST131 clone and pAmpC-producing E. coli in Japan are 47 
poor. In this study, we investigated the prevalence and characteristics of the ST131 clone and 48 
pAmpC-producing E. coli in the Kyoto and Shiga regions of Japan. 49 
 50 
 51 
2. Materials and methods 52 
2.1. Bacterial isolates 53 
 This study was conducted at 5 acute care hospitals in Japan: 3 municipal hospitals and 2 54 
university hospitals in the Kyoto and Shiga regions of Japan. All of the E. coli isolates collected from 55 
both in-patients and out-patients between June 2010 and December 2010 were eligible for the study. 56 
In each hospital, microbiological speciation was conducted using the Vitek2 system (bioMérieux, 57 
Marcy l’Etoile, France) or the MicroScan system (Siemens Healthcare diagnostics, Tokyo, Japan). 58 
The ESBL screening test was performed according to the CLSI microdilution methodology 59 
(cefotaxime, ceftriaxone, ceftazidime, cefpodoxime, or aztreonam) [4]. 60 
 61 
2.2. Molecular analysis 62 
Only the first isolate from each patient that was positive in the ESBL screen was sent to a 63 
reference laboratory (Kyoto University) and subjected to PCR amplification and sequencing of the 64 
blaSHV, blaTEM, blaOXA-1, and blaCTX-M genes and the 6 main groups of pAmpC-type genes [5]. All of 65 
the isolates with ESBL or pAmpC genes were further characterised based on their plasmid-mediated 66 
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quinolone resistance determinants (qnrA, qnrB, qnrC, qnrS, and aac(6’)-Ib-cr) [5], their phylogenetic 67 
groups using triplex PCR (A, B1, B2, D, and non-typable) [5], integrases [6], and plasmid replicon 68 
typing [7] as has been previously described. Isolates that belonged to phylogenetic group B2 and were 69 
O25b PCR positive and O25b-pabB PCR positive were considered to belong to the ST131 clone [8]. 70 
Five selected ST131 isolates identified by these presumptive methods were confirmed by multilocus 71 
sequence typing according to the E. coli MLST Web site (http://mlst.ucc.ie/mlst/dbs/Ecoli). Random 72 
amplified polymorphic DNA (RAPD) fingerprinting using a DAF4 primer was also performed [5], 73 
and the profiles were analysed by GelCompar II, version 4.6 (Applied Maths, Sint-Martens-Latem, 74 
Belgium). Isolates with 100% similarity were designated as indistinguishable following the criteria by 75 
Tenover et al. [9]. Ciprofloxacin-non-susceptible isolates were sequenced to determine the quinolone 76 
resistance-determining regions (QRDRs) of gyrA and parC [10], and the correlated amino acids were 77 
compared with the corresponding regions of E. coli K-12 (GenBank accession no. NC000913). 78 
 79 
2.3. Antimicrobial susceptibility testing 80 
The antibiotic susceptibility was evaluated by microdilution using Dry Plate Eiken (Eiken, 81 
Tokyo, Japan) following CLSI specifications and interpreted according to the 2009 and 2011 CLSI 82 
criteria [4]. The ESBL confirmation test was performed using the double-disk synergy test following 83 
the CLSI guidelines [4]. 84 
 85 
2.4. Statistical analysis 86 
 Categorical variables were compared using the Fisher’s exact test. A P value less than 0.05 87 
was considered statistically significant. 88 
 89 
3. Results and discussion 90 
3.1. Prevalences of pAmpC or ESBL producers 91 
During the study period, E. coli was isolated from a total of 1327 patients from 5 hospitals (Table 1). 92 
Of those isolates, 172 (13.0%) were positive in the ESBL screen. The PCR analysis identified 23 93 
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pAmpC producers and 129 ESBL producers, 4 of which were positive for both the pAmpC and the 94 
ESBL genes. The remaining 24 isolates contained neither pAmpC nor ESBL. The prevalence of 95 
pAmpC producers was 1.7%. CMY-2 was the most prevalent pAmpC type. Surveillance conducted 96 
between 2002 and 2008 in the Kinki region, which includes our study sites, showed that CMY-2 type 97 
was most prevalent [11]. However, the prevalence rate from our data (1.7%) seems to be substantially 98 
higher (0.1%) than that found previously. One possible explanation for this difference is that the 99 
prevalence has varied over time. We did not assess the yearly variation, but the prevalence of pAmpC 100 
producers has been increasing; for example, a Spanish study reported that the prevalence increased 101 
from 0.04% in 1997 to 1.1% in 2007. The prevalence of ESBL producers was 9.7%. In 2003, inpatient 102 
urine collected in 37 hospitals in Japan was studied, and the prevalence was 14% [12]. The SMART 103 
surveillance in 2009 reported a diverse prevalence within the Asia-Pacific region that ranged from 104 
2.0% in Australia to 65.4% in China [13]. The prevalence of ESBL producers and pAmpC producers 105 
were higher in the 2 university hospitals than in the 3 municipal hospitals, which may be associated 106 
with the fact that university hospitals had less frequent community-acquired infections and had 107 
patients with more severe underlying diseases than municipal hospitals. 108 
 109 
3.2. Antimicrobial susceptibility 110 
Table 2 shows the characteristics of the pAmpC producers and the ESBL producers. The 111 
most frequent isolation source was urine. All of the isolates were susceptible to imipenem (minimum 112 
inhibitory concentration ≤1 g/mL). Almost all of the ESBL producers were judged to be resistant to 113 
third-generation cephalosporins by the old CLSI breakpoints (prior to 2010) due to the positive results 114 
of the ESBL confirmation test. However, the revised breakpoints classified 66% of ESBL producers 115 
as susceptible to ceftazidime. This finding can be explained by the fact that 87% (42/48) of 116 
CTX-M-14-producers and 13% (4/31) of CTX-M-15-producers were susceptible to ceftazidime. This 117 
phenomenon is worth noting when implementing the revised breakpoints where CTX-M-14 is 118 
prevalent. 119 
Less than one half of the pAmpC producers were determined to be resistant to 120 
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third-generation cephalosporins by old breakpoints, as all the isolates were negative in the ESBL 121 
confirmation test. The revised breakpoints correctly classified more than 90% of the pAmpC 122 
producers as resistant to third-generation cephalosporins. In Japan, the old breakpoints are still used, 123 
and the phenotype tests for the detection of pAmpC producers are rarely conducted. Furthermore, 124 
pAmpC producers are likely resistant to cefmetazole and piperacillin-tazobactam because of the 125 
activity of the pAmpC enzyme [3]. However, fewer than half were judged to be resistant. When ESBL 126 
screening-positive and ESBL confirmation-negative isolates are detected, the use of third-generation 127 
cephalosporins, cephamycins, or β-lactam/β-lactam inhibitors requires caution irrespective of the 128 
susceptibilities of the isolates because the clinical efficacies of these drugs have not yet been 129 
established. 130 
Twenty-four isolates without pAmpC or ESBL genes had reduced susceptibility rates to 131 
β-lactam/β-lactam inhibitors (29% for ampicillin/sulbactam and 46% for piperacillin/tazobactam), and 132 
elevated chromosomal AmpC was a suggested mechanism of resistance. 133 
 134 
3.3 Phylogenetic group, CTX-M type, and the ST131 clone isolates 135 
Virulent phylogenetic groups B2 and D were prevalent in both pAmpC and ESBL producers. 136 
The CTX-M type, which is associated with the international emergence of the O25b-ST131-B2 clone, 137 
is now spreading worldwide [1]. CTX-M-15 is most closely associated with the ST131 clone, and thus 138 
is the most widely distributed CTX-M subtype. In our study, CTX-M-14 was the most prevalent 139 
ESBL, and CTX-M-15 was the second prevalent. Among 125 ESBL producers, 51 isolates of the 140 
ST131 clone (41%) were found. CTX-M-27 (41%) and CTX-M-15 (28%) were the most prevalent 141 
ESBLs in the ST131 clone isolates; however, CTX-M-27 was rarely found in non-ST131 clone 142 
isolates (2%). CTX-M-14 was the most frequent ESBL in non-ST131 isolates (41%). In the previous 143 
Japanese nationwide surveillance study, a significant portion of ESBL producers belonged to the 144 
ST131 and ST38 clones (approximately 20% each [14]. Most of the ST131 clone isolates contained 145 
CTX-M-14, but none of them contained CTX-M-15 or CTX-M-27 [14]. The prevalence of the ST131 146 
clone has doubled, and the distribution of CTX-M types was quite different from that found in a 147 
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previous study. RAPD analysis showed that 135 of the 148 pAmpC or ESBL producers had 148 
distinguishable patterns. All of the 13 other isolates belonged to the ST131 clone and were composed 149 
of 1 cluster of 3 isolates and 5 clusters of 2 isolates. These results suggest that the ST131 clone is a 150 
dominant and unique clone among ESBL producers in our region. 151 
The ST131 clone frequently contained genes for TEM-1, OXA-1, aac(6’)-Ib-cr, and 152 
ciprofloxacin resistance [2]. In our study, the ST131 clone isolates had a higher ciprofloxacin 153 
non-susceptible rate (85%) than non-ST131 clone isolates (46%). Table 3 shows all of the 154 
ciprofloxacin non-susceptible isolates that had at least 3 mutations in QRDRs. All of the 46 155 
ciprofloxacin non-susceptible ST131 clone isolates had double mutations both in GyrA (S83L and 156 
D87N) and ParC (S80I and E84V). This genotype was rarely found in the previous study in Asia [10]. 157 
On the contrary, 30 of 43 (70%) non-ST131 clone isolates had double mutations in GyrA (S83L and 158 
D87N) and a single mutation in ParC (S80I). This genotype was found worldwide, including in Asia 159 
[10]. A significantly smaller number of the ST131 clone isolates had TEM-1, which differed from 160 
previous studies [2]. The ST131 clone isolates frequently contained OXA-1 and aac(6’)-Ib-cr, but the 161 
difference was not statistically significant. The ST131 clone isolates more frequently contained 162 
plasmid replicons for both IncFIA and IncFIB. Associations between CTX-M-15 producers and both 163 
IncFIA and IncFIB have been reported [7]. 164 
The ST131 clone accounted for only 2 of 19 pAmpC producing-isolates. These two isolates 165 
were susceptible to ciprofloxacin. The low prevalence of pAmpC-producing ST131 is consistent with 166 
the results of studies from Europe, which found a prevalence of less than 10% [15]. IncI1 was more 167 
frequently found in pAmpC producers than in ESBL producers. A Norwegian study reported a high 168 
prevalence of IncI1 among CMY-2 producers [15]. 169 
 170 
4. Conclusion 171 
We found that 1.7% of E. coli isolates from clinical specimens were pAmpC producers. 172 
Among the ESBL producers, 41% were isolates of the ST131 clone, and these isolates were 173 
characterised by ciprofloxacin non-susceptibility with quadruple mutations in QRDRs, the presence of 174 
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Table 1. Prevalences of ESBL-producing and pAmpC-producing E. coli in each hospital. 228 
Hospital 
Type of 









Both pAmpC and 
ESBL 
A Municipal 350 35 (10.0%) 20 (5.7%) 20 (5.7%) 4 (1.1%) 1 (0.3%) 
B University 253 42 (16.6%) 33 (13.0%) 32 (12.6%) 7 (2.8%) 2 (0.8%) 
C Municipal 173 18 (10.4%) 17 (9.8%) 17 (9.8%) 1 (0.6%) 0 (0.0%) 
D Municipal 272 28 (10.3%) 23 (8.5%) 23 (8.5%) 5 (1.8%) 1 (0.4%) 
E University 279 49 (17.6%) 38 (13.6%) 37 (13.3%) 6 (2.2%) 0 (0.0%) 
A, C, and D Municipal 795 81 (10.2%) 60 (7.5%) 60 (7.5%) 10 (1.3%) 2 (0.3%) 
B and E University 532 91 (17.1%) 71 (13.3%) 69 (13.0%) 13 (2.4%) 2 (0.4%) 
Total  1327 172 (13.0%) 131 (9.9%) 129 (9.7%) 23 (1.7%) 4 (0.3%) 
All of the first isolates from each patient that were positive in the ESBL screening test were collected. The prevalences of ESBL producers and 229 
pAmpC producers were higher in the 2 university hospitals than in the 3 municipal hospitals (P=0.001 and P=0.13, respectively). 230 
a





Table 2. Sources, in-vitro susceptibilities, and molecular characteristics of pAmpC-producing and ESBL-producing E. coli. 234 
 
pAmpC only ESBL only 
pAmpC 
 and ESBL  ST131 clone 
Non-ST 131 
clone  
Characteristic (n=19) (n=125) (n=4) P value
a
 (n=54) (n=94) P value 
Source of isolates             
Urine 11 (58%) 83 (66%) 2 (50%) 0.61 40 (74%) 56 (60%) 0.11 
Pus 4 (21%) 14 (11%) 0 (0%) 0.26 7 (13%) 11 (12%) 0.80 
 Blood 1 (5%) 9 (7%) 1 (25%) 1 1 (2%) 10 (11%) 0.06 
 Sputum 0 (0%) 5 (4%) 0 (0%) 1 5 (9%) 0 (0%) 0.006 
 Bile 0 (0%) 4 (3%) 1 (25%) 1 0 (0%) 5 (5%) 0.16 
 Others 3 (16%) 10 (8%) 0 (0%) 0.38 1 (2%) 12 (13%) 0.03 
In-vitro susceptibility             
 Cefepime 19 (100%) 86 (69%) 3 (75%) 0.002 39 (72%) 69 (73%) 1 
 Cefepime (old BP) 19 (100%) 0 (0%) 1 (25%) <0.001 2 (4%) 18 (19%) 0.01 
 Cefotaxime 0 (0%) 2 (2%) 0 (0%) 1 1 (2%) 1 (1%) 1 
 Cefotaxime (old BP) 15 (79%) 0 (0%) 1 (25%) <0.001 2 (4%) 14 (15%) 0.05 
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 Ceftazidime 1 (5%) 82 (66%) 0 (0%) <0.001 30 (56%) 53 (56%) 1 
Ceftazidime (old BP) 9 (47%) 0 (0%) 1 (25%) <0.001 1 (2%) 9 (10%) 0.09 
Aztreonam 12 (63%) 50 (40%) 1 (25%) 0.08 21 (39%) 42 (45%) 0.61 
 Aztreonam (old BP) 15 (79%) 0 (0%) 1 (25%) <0.001 2 (4%) 14 (15%) 0.05 
 Cefmetazole 10 (53%) 122 (98%) 2 (50%) <0.001 52 (96%) 82 (87%) 0.08 
 Ampicillin-sulbactam 1 (5%) 45 (36%) 0 (0%) 0.007 25 (46%) 21 (22%) 0.003 
 Piperacillin-tazobactam 11 (58%) 96 (77%) 1 (25%) 0.09 47 (87%) 61 (65%) 0.004 
 Imipenem 19 (100%) 125 (100%) 4 (100%) 1 54 (100%) 94 (100%) 1 
 Amikacin 19 (100%) 125 (100%) 4 (100%) 1 54 (100%) 94 (100%) 1 
 Gentamicin 18 (95%) 103 (82%) 4 (100%) 0.31 48 (89%) 77 (82%) 0.35 
 Ciprofloxacin 14 (74%) 43 (34%) 2 (50%) 0.002 8 (15%) 51 (54%) <0.001 
Trimethoprim-sulfamethoxaz
ole 
10 (53%) 67 (54%) 2 (50%) 1 31 (57%) 48 (51%) 0.50 
 Minocycline 11 (58%) 93 (74%) 2 (50%) 0.17 46 (85%) 60 (64%) 0.008 
 Colistin 19 (100%) 125 (100%) 4 (100%) 1 54 (100%) 94 (100%) 1 
ESBL confirmation test 0 (0%) 125 (100%) 3 (75%) <0.001 52 (96%) 76 (81%) 0.01 
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Resistance gene             
 CMY-2 18 (95%) 0 (0%) 4 (100%) <0.001 2 (4%) 20 (21%) 0.003 
 DHA-1 1 (5%) 0 (0%) 0 (0%) 0.14 1 (2%) 0 (0%) 0.37 
 CTX-M-14b 0 (0%) 50 (40%) 0 (0%) <0.001 11 (20%) 39 (41%) 0.01 
 CTX-M-15b 0 (0%) 33 (26%) 1 (25%) 0.007 15 (28%) 18 (19%) 0.31 
 CTX-M-27 0 (0%) 24 (19%) 0 (0%) 0.04 22 (41%) 2 (2%) <0.001 
 CTX-M-2 0 (0%) 10 (8%) 1 (25%) 0.36 1 (2%) 10 (11%) 0.06 
 CTX-M-24 0 (0%) 4 (3%) 0 (0%) 1 2 (4%) 2 (2%) 0.62 
 CTX-M-1 0 (0%) 2 (2%) 2 (50%) 1 0 (0%) 2 (2%) 1 
 CTX-M-3 0 (0%) 0 (0%) 1 (25%) 1 0 (0%) 1 (1%) 0.37 
 CTX-M-9 0 (0%) 2 (2%) 0 (0%) 1 0 (0%) 1 (1%) 0.37 
 CTX-M-44 0 (0%) 1 (1%) 1 (25%) 1 0 (0%) 1 (1%) 0.37 
 CTX-M-65 0 (0%) 1 (1%) 0 (0%) 1 0 (0%) 1 (1%) 0.37 
 SHV type ESBL 0 (0%) 3 (2%) 0 (0%) 1 1 (2%) 2 (2%) 1 
 TEM-1 8 (42%) 45 (36%) 2 (50%) 0.62 12 (22%) 43 (46%) 0.005 





 1 (5%) 3 (2%) 0 (0%) 0.44 1 (2%) 3 (3%) 0.46 
 aac(6’)-Ib-cr 0 (0%) 5 (4%) 0 (0%) 1 4 (7%) 1 (1%) 0.06 
Phylogenetic group             
 A 2 (11%) 4 (3%) 0 (0%) 0.18 0 (0%) 6 (6%) 0.08 
 B1 2 (11%) 9 (7%) 1 (25%) 0.64 0 (0%) 12 (13%) 0.004 
 B2 6 (32%) 66 (53%) 2 (50%) 0.14 54 (100%) 20 (21%) <0.001 
 D 7 (37%) 43 (34%) 1 (25%) 0.80 0 (0%) 51 (54%) <0.001 
 Non-typable 2 (11%) 3 (2%) 0 (0%) 0.13 0 (0%) 5 (5%) 0.16 
ST131 clone 2 (11%) 51 (41%) 1 (25%) 0.01 54 (100%) 0 (0%) <0.001 
Class 1 integrase
d
 10 (53%) 61 (49%) 2 (50%) 0.81 25 (46%) 48 (51%) 0.61 
Plasmid replicon type
e
             
 IncFIA 0 (0%) 20 (16%) 1 (25%) 0.07 13 (24%) 8 (9%) 0.01 
 IncFIA and IncFIB 4 (21%) 51 (41%) 1 (25%) 0.13 33 (61%) 23 (24%) <0.001 
 IncFIB 6 (32%) 29 (23%) 1 (25%) 0.41 5 (9%) 31 (33%) 0.001 
 IncI1 10 (53%) 26 (21%) 4 (100%) 0.008 7 (13%) 33 (35%) 0.004 
The data are presented as the number (%). 235 
All in vitro susceptibilities were evaluated using the revised CLSI breakpoints for 2011 except those for the antibiotics labeled “old BP”; for these 236 
17 
 
antibiotics, the susceptibility was evaluated using the old CLSI breakpoints for 2009 with modification of the category if the ESBL confirmation test 237 
was positive. For colistin, all of the isolates in this study had minimum inhibitory concentrations of  2 μg/mL. 238 
a
 P value for the comparison between pAmpC-only and ESBL-only isolates. 239 
b Two ESBL-producing isolates (one ST131 clone and one non-ST131 clone) were positive for CTX-M-14 and CTX-M-15. 240 
c qnrB was found in the pAmpC and ST131 group. qnrS was found in the ESBL and non-ST131 group. 241 
d 










Table 3. Molecular mechanism of quinolone resistance among ciprofloxacin non-susceptible ESBL-producing E. coli. 245 
 
 Amino acid mutations in QRDR  
Number of isolates 
with aac(6’)-Ib-cr Clone type 
Number of 
isolates 
GyrA  ParC  
83 87  80 84  
ST131 clone 46 L N  I V  4 
Non-ST131 clone 30 L N  I E  0 
5 L N  I G  1 
2 L N  I V  0 
2 L Y  I E  0 
1 L N  I A  0 
1 L N  I K  0 
1 L N  I S  0 
1 L N  R E  0 
Wild type (E.coli K-12) - S D  S E  - 
All of these isolates lacked qnr. 246 
